Oncology Practice Management Issues

February 2018, Vol 8, No 2

Switching on the Light: A Model Immunotherapy Program for Oncology Practices

Gail Thompson


Immunotherapy is one of the hottest concepts in oncology care. Also called biologic therapy, this type of cancer treatment boosts the body’s own natural defenses to fight cancers. Ann M. McGreal, RN, OCN, Oncology Nurse Clinician, and Sigrun Hallmeyer, MD, Senior Executive Director, Advocate Medical Group, Park Ridge, IL, shared their experience with immunotherapy at the ACCC National Oncology Conference in October 2017 in Nashville. [ Read More ]

Silent Patients Find Their Voices Through an Advocate’s Journey

Meg Barbor, MPH

Patients Perspectives

Advocacy usually begins with personal crisis and the need for support, but it eventually moves on to sharing experiences and information with others, speaking out in public forums, and working to influence change, suggested Musa Mayer, breast cancer survivor and advocate, at the recent ESMO International Consensus Conference for Advanced Breast Cancer in Lisbon, Portugal, where she received the ABC4 Award in recognition of her 25 years of advocacy on behalf of patients with advanced breast cancer. [ Read More ]

The Challenges of Oral Cancer Drugs Use and Side-Effects Management

Meg Barbor, MPH

Side-Effects Management

There is only one “king of the road” when it comes to dealing with the adverse side effects of oral cancer drugs, and that is not the healthcare professional, according to Christine B. Boers-Doets, MSc, of the Netherlands Leiden University Medical Center, author of The TARGET System, and creator of the 7 Pillars of Ultimate Drug Success formula. She discussed this topic at the recent ESMO International Consensus Conference for Advanced Breast Cancer in Lisbon, Portugal. [ Read More ]

Are You Considering Nurse Fatigue in Your Practice?

Nurse Fatigue

On January 11, 2018, the American Academy of Nursing (AAN) released its position statement in recognition that safe nursing practice requires adequate, high-quality sleep to allow them to contribute to patient care safely. The statement was also published in the November/December 2017 issue of Nursing Outlook. [ Read More ]

CAR T-Cell Therapy Makes Significant Inroads in Lymphoma: Kymriah and Yescarta Show Durable Remissions

Phoebe Starr

ASH 2017 Highlights, Hematologic Malignancies, Lymphoma

The data for CD19-directed chimeric antigen receptor (CAR) T-cell therapy continue to show excellent and durable responses in patients with lymphoma who have no other treatment options. Two studies presented at ASH 2017 provide encouraging news for 2 new drugs, including long-term follow-up of the pivotal ZUMA-1 study of the CAR T-cell therapy axicabtagene ciloleucel (Yescarta), and primary results from the JULIET study of tisagenlecleucel (Kymriah). [ Read More ]

CAR T-Cell Therapy Shows “Impressive” Results in Multiple Myeloma

Wayne Kuznar

ASH 2017 Highlights, Hematologic Malignancies, Multiple Myeloma

Atlanta, GA—Although chimeric antigen receptor (CAR) T-cell therapies directed against the CD19 protein garnered much attention at ASH 2017, CAR T-cells targeting B-cell maturation antigen (BCMA), a protein expressed nearly universally on multiple myeloma cells, were found to be remarkably effective in patients with heavily pretreated multiple myeloma. [ Read More ]